Our study indicates SESN1 functions as a new tumor suppressor gene via a MyD88‐dependent TLR signaling pathway in NB, and SENS1 and TLR signaling pathway may be new therapy targets for NB clinical treatment. This evidence concerns the gene SESN1 and neuroblastoma.